A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Solid Tumors
What the trial is testing?
Durvalumab, LY3022855, Tremelimumab
Could I receive a Placebo?
No
Enrollment Goal
72
Trial Dates
Jun 16, 2016 - Dec 14, 2018
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.